The suprachoroidal space is extremely promising as a micro-interventional surgical target in glaucoma. Enhancing suprachoroidal aqueous outflow is the primary mechanism for prostaglandin analogues, the current best-in-class medical treatment for glaucoma. Additionally, in vitro studies have shown that a large pressure gradient can be achieved between the anterior chamber and the suprachoroidal space. First-generation MIGS technologies that targeted the suprachoroidal space demonstrated superior intraocular pressure (IOP) lowering effects and ease of use.
The question remained, how can the suprachoroidal space be more reliably and safely stented? Can it be done without hardware?
Recently at the Glaucoma 360 meeting, Dr. Weinreb unveiled a new revolutionary MIGS approach for hardware-free stenting and reinforcement of the suprachoroidal space. This approach uses Iantrek, Inc.’s micro-interventional technology in combination with bio-tissue .
Watch the whole video below
